[HTML][HTML] Atorvastatin
LA McIver, MS Siddique - 2017 - europepmc.org
Objectives: Describe the indications for atorvastatin therapy. Identify potential adverse
events when using therapy with atorvastatin. Outline the appropriate follow-up and …
events when using therapy with atorvastatin. Outline the appropriate follow-up and …
Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors
PH Chong - Annals of Pharmacotherapy, 2002 - journals.sagepub.com
OBJECTIVE: To review relevant literature and provide an opinion on the class effect of
hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). DATA SOURCES: Primary …
hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). DATA SOURCES: Primary …
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial
DR Illingworth, JR Crouse III… - … medical research and …, 2001 - Taylor & Francis
Objective: At higher doses, simvastatin has been shown to produce significantly greater
increases in high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) AI than …
increases in high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) AI than …
Long-term safety and efficacy profile of simvastatin
SJ Boccuzzi, TS Bocanegra, JF Walker… - The American journal of …, 1991 - Elsevier
Abstract Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, has
been administered to approximately 2,400 patients with primary hypercholesterolemia with a …
been administered to approximately 2,400 patients with primary hypercholesterolemia with a …
Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors
PH Chong, JD Seeger - Pharmacotherapy: The Journal of …, 1997 - Wiley Online Library
Atorvastatin calcium is an HMG‐coenzyme A (CoA) reductase inhibitor that was approved by
the Food and Drug Administration on December 17, 1996. Like other such agents, it inhibits …
the Food and Drug Administration on December 17, 1996. Like other such agents, it inhibits …
Clinically relevant differences between the statins: implications for therapeutic selection
PH Chong, JD Seeger, C Franklin - The American journal of medicine, 2001 - Elsevier
Although the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, share a
common lipid-lowering effect, there are differences within this class of drugs. The low …
common lipid-lowering effect, there are differences within this class of drugs. The low …
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and …
P Alaupovic, T Heinonen, L Shurzinske, DM Black - Atherosclerosis, 1997 - Elsevier
The effects of atorvastatin (lipitor) on cholesterol-rich and triglyceride-rich lipoproteins were
evaluated in this multicenter trial. Following a 6-week baseline period, 47 patients with …
evaluated in this multicenter trial. Following a 6-week baseline period, 47 patients with …
Comparison of atorvastatin alone versus simvastatin ± cholestyramine in the management of severe primary hypercholesterolemia (The Six Cities Study)
LA Simons - Australian and New Zealand journal of medicine, 1998 - Wiley Online Library
Background: Atorvastatin is a new member of the class of drugs which inhibit the enzyme
Hydroxy‐Methylglutaryl Co‐A reductase, the rate limiting step in cholesterol biosynthesis …
Hydroxy‐Methylglutaryl Co‐A reductase, the rate limiting step in cholesterol biosynthesis …
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
A Dart, G Jerums, G Nicholson, M d'Emden… - The American journal of …, 1997 - Elsevier
We directly compared the safety and efficacy of atorvastatin and simvastatin in
hypercholesterolemic patients. This 1-year, randomized, double-blind study was performed …
hypercholesterolemic patients. This 1-year, randomized, double-blind study was performed …